VTL Vital Therapies, Inc.

2.83
-0.375  -12%
Previous Close 3.20
Open 3.15
Price To book 1.60
Market Cap 119.23M
Shares 42,207,000
Volume 144,356
Short Ratio 57.10
Av. Daily Volume 128,417

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 VTI-208 trial failed. New VTI-308 trial initiated May 2016. Data due mid 2018.
VTI-308
Alcohol-induced liver decompensation, or AILD
Terminated September 2015 in order to reduce costs
ELAD (VTI-210)
Severe acute alcoholic hepatitis
Terminated September 2015 in order to reduce costs
ELAD (VTI-212)
Fulminant hepatic failure, or FHF, or surgery-induced acute liver failure, or SILF